Latest FY 2025 Results Set the Stage for Aspen Aerogels

Aspen Aerogels (ASPN) has just wrapped up FY 2025 with Q4 revenue of about US$41.3 million and a basic EPS loss of US$0.88, capping a year in which trailing twelve month revenue came in at roughly US$271.1 million and EPS on the same basis was a loss of US$4.73. Over recent quarters the company has seen quarterly revenue shift from US$123.1 million in Q4 2024 to US$78.7 million in Q1 2025, US$78.0 million in Q2, US$73.0 million in Q3 and US$41.3 million in Q4. Quarterly EPS moved from a profit of US$0.14 in Q4 2024 to losses of US$3.67, US$0.11, US$0.08 and US$0.88 across 2025, leaving investors focused squarely on how quickly margins can stabilize from here.

See our full analysis for Aspen Aerogels.

With the headline numbers on the table, the next step is to see how this earnings profile lines up against the widely followed narratives around Aspen Aerogels, highlighting where the story is reinforced and where the recent results push back against expectations.

TTM loss of US$389.6 million keeps profitability in focus

• On a trailing twelve month basis, Aspen Aerogels reported revenue of US$271.1 million and a net loss of US$389.6 million, with basic EPS at a loss of US$4.73, which is a clear contrast to the small profit reported on the same basis a year earlier.
• Bears point to those trailing losses and argue that even with revenue described as growing around 18% per year, the negative net margin and five year history of widening losses, roughly 49.6% per year, keep profitability risk front and center.
  • That view leans on the FY 2025 pattern where each quarter showed a loss, including a US$72.9 million loss in Q4 and a US$301.2 million loss in Q1. This reinforces concerns about earnings quality rather than just a single tough period.
  • At the same time, the expectation that margins could eventually improve challenges the idea that the current loss profile automatically rules out future profit. As a result, the bearish stance rests heavily on how persistent these recent loss levels prove to be.

Over the last year, skeptics have treated the very large trailing losses as a stress test for the whole business model, and these FY 2025 numbers give you a concrete sense of the scale they are focused on. 🐻 Aspen Aerogels Bear Case

Volatile quarterly net income feeds into bearish worries

• Quarterly net income swung from an 11.4 million profit in Q4 2024 to a US$301.2 million loss in Q1 2025 and a US$72.9 million loss in Q4 2025, so the full year profile is shaped by several sizable loss quarters rather than a smooth trend.
• Critics highlight this pattern as backing the more cautious narrative that heavy capital needs and uneven demand, especially in energy industrial and subsea projects, can quickly turn modest profits into substantial losses when volumes soften.
  • The sharp change from the Q4 2024 profit to consecutive FY 2025 losses, including US$9.1 million and US$6.3 million losses in Q2 and Q3, fits the bearish concern that earnings are sensitive to project timing and mix.
  • Those swings line up with comments that project based revenues in areas like subsea and LNG can drop quickly. This means even a company with strong product positioning can see net income move from profit to loss when that work slows.

P/S of 0.8x and DCF fair value of US$15.47 challenge the loss story

• With a current share price of US$2.57, a P/S multiple of 0.8x sits below both the US chemicals industry average of 1.2x and a peer average of 1.0x, while a stated DCF fair value of US$15.47 is materially higher than where the stock trades today.
• Bulls argue that, despite the recent losses, strong forecasted earnings growth of about 93.7% per year and an expectation of profitability within three years could make the current valuation look conservative if those margin and growth assumptions play out.
  • The bullish case leans on revenue being described as growing faster than a 10.4% US market benchmark and on projections that profit margins could move from a deeply negative level today into positive double digits over the coming years.
  • This creates a direct tension between the trailing net loss of US$389.6 million and the idea that, if forecasted margins and earnings materialize, today’s 0.8x P/S and the gap to the US$15.47 DCF fair value may be reflecting execution risk rather than a permanently impaired business.

If you are weighing that tradeoff between heavy recent losses and the projected move to profit, it can help to see how bullish investors frame the full story for Aspen Aerogels, from growth drivers to risks. 🐂 Aspen Aerogels Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Aspen Aerogels on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Reading this, you can see why opinions on Aspen Aerogels are split. It is worth moving quickly and weighing the numbers yourself using our breakdown of 3 key rewards and 1 important warning sign.

See What Else Is Out There

Heavy trailing losses of US$389.6 million, quarterly earnings swings, and ongoing EPS pressure keep profitability risk at the center of the Aspen Aerogels story.

If that level of earnings volatility makes you uneasy, now is a good time to look at our 80 resilient stocks with low risk scores that focuses on companies with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.